Indaptus Therapeutics Inc

Abbott Cooper PLLC has announced an investigation into potential legal claims on behalf of Indaptus Therapeutics, Inc. stockholders who held shares prior to December 22, 2025. The investigation focuses on whether the Indaptus Board violated its fiduciary duties in connection with a private placement of preferred stock. Stockholders who have held Indaptus shares since before that date are encouraged to contact Abbott Cooper PLLC at no cost or obligation. The firm handles cases on a contingency fee basis, meaning there is no cost to stockholders unless a recovery is obtained.